Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series

Le, X., Eisert, A., Hsia, T. C., Raut, N. V., Ahmad, A., Chan, O. S. H., De Bondt, C., Farrugia, D., Froesch, P., González-Cao, M., Hendriks, L., Hochmair, M. J., Mazieres, J., O'Sullivan, H., Popat, S., Samol, J., van der Wekken, A. J., Yang, T. Y., Tho, L. M., Himpe, U., … Chang, G. C. (2025). Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series. Clinical lung cancer, 26(4), 338–346.e1. https://doi.org/10.1016/j.cllc.2025.02.013

DOI

10.1016/j.cllc.2025.02.013

URI

https://hdl.handle.net/20.500.14709/1424

License

CC BY 4.0

cb

Usage rights

CC BY 4.0

License

https://creativecommons.org/licenses/by/4.0/